U.S. Markets closed
  • S&P Futures

    4,341.25
    +23.50 (+0.54%)
     
  • Dow Futures

    34,174.00
    +131.00 (+0.38%)
     
  • Nasdaq Futures

    14,133.50
    +146.75 (+1.05%)
     
  • Russell 2000 Futures

    1,930.30
    +2.00 (+0.10%)
     
  • Crude Oil

    87.18
    +0.57 (+0.66%)
     
  • Gold

    1,795.40
    +2.30 (+0.13%)
     
  • Silver

    22.68
    +0.00 (+0.02%)
     
  • EUR/USD

    1.1151
    +0.0004 (+0.0335%)
     
  • 10-Yr Bond

    1.8070
    -0.0410 (-2.22%)
     
  • Vix

    30.49
    -1.47 (-4.60%)
     
  • GBP/USD

    1.3391
    +0.0009 (+0.0696%)
     
  • USD/JPY

    115.4270
    +0.1250 (+0.1084%)
     
  • BTC-USD

    37,173.33
    +220.42 (+0.60%)
     
  • CMC Crypto 200

    842.81
    +23.30 (+2.84%)
     
  • FTSE 100

    7,554.31
    +84.53 (+1.13%)
     
  • Nikkei 225

    26,446.73
    +276.43 (+1.06%)
     

If You Had Bought CollPlant Biotechnologies (NASDAQ:CLGN) Stock Three Years Ago, You Could Pocket A 146% Gain Today

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • CLGN

While CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 15% in the last quarter. But that doesn't change the fact that the returns over the last three years have been very strong. Indeed, the share price is up a very strong 146% in that time. It's not uncommon to see a share price retrace a bit, after a big gain. The thing to consider is whether the underlying business is doing well enough to support the current price.

See our latest analysis for CollPlant Biotechnologies

CollPlant Biotechnologies isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In the last 3 years CollPlant Biotechnologies saw its revenue grow at 44% per year. That's well above most pre-profit companies. Along the way, the share price gained 35% per year, a solid pop by our standards. This suggests the market has recognized the progress the business has made, at least to a significant degree. That's not to say we think the share price is too high. In fact, it might be worth keeping an eye on this one.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

Take a more thorough look at CollPlant Biotechnologies' financial health with this free report on its balance sheet.

A Different Perspective

CollPlant Biotechnologies shareholders are up 39% for the year. But that was short of the market average. The silver lining is that the gain was actually better than the average annual return of 0.9% per year over five year. This suggests the company might be improving over time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 3 warning signs for CollPlant Biotechnologies you should be aware of, and 2 of them don't sit too well with us.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.